RPG Life Sciences Ltd.
Q3FY23 Quarterly Result Announced for RPG Life Sciences Ltd.
Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results:
Q3FY23 & 9MFY23:
- RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY.
- Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY.
- Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23.
Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY.
Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.”